Prism Medical (PM) Given Coverage Optimism Score of 1.86

Share on StockTwits

Press coverage about Prism Medical (CVE:PM) has trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prism Medical earned a media sentiment score of 1.86 on their scale. InfoTrie also assigned news coverage about the company an news buzz score of 4 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Prism Medical stock traded up C$0.34 during midday trading on Friday, reaching C$80.44. 5,784,382 shares of the stock traded hands, compared to its average volume of 6,260,029. Prism Medical has a fifty-two week low of C$79.71 and a fifty-two week high of C$123.55.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at

About Prism Medical

Prism Medical Ltd. is a provider of durable medical equipment and services used to the mobility challenged individuals. The Company’s business units include Prism Medical Canada and Prism Medical United States. The Company’s products are marketed under the brand names of Prism Medical, Ergosafe, Waverley Glen and Nightingale in the home care, acute care and long-term care markets in the United States and Canada.

Featured Story: What is insider trading?

Receive News & Ratings for Prism Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prism Medical and related companies with's FREE daily email newsletter.

Leave a Reply